CA2550727A1 - Traitement de l'ischemie coronaire ou peripherique - Google Patents

Traitement de l'ischemie coronaire ou peripherique Download PDF

Info

Publication number
CA2550727A1
CA2550727A1 CA002550727A CA2550727A CA2550727A1 CA 2550727 A1 CA2550727 A1 CA 2550727A1 CA 002550727 A CA002550727 A CA 002550727A CA 2550727 A CA2550727 A CA 2550727A CA 2550727 A1 CA2550727 A1 CA 2550727A1
Authority
CA
Canada
Prior art keywords
heparin
fgf
expression vector
growth factor
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002550727A
Other languages
English (en)
Inventor
Andre Uzan
Alexis Caron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Centelion SAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2550727A1 publication Critical patent/CA2550727A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002550727A 2003-12-29 2004-12-29 Traitement de l'ischemie coronaire ou peripherique Abandoned CA2550727A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53299303P 2003-12-29 2003-12-29
US60/532,993 2003-12-29
PCT/EP2004/014910 WO2005063807A2 (fr) 2003-12-29 2004-12-29 Traitement de l'ischemie coronaire ou peripherique

Publications (1)

Publication Number Publication Date
CA2550727A1 true CA2550727A1 (fr) 2005-07-14

Family

ID=34738851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002550727A Abandoned CA2550727A1 (fr) 2003-12-29 2004-12-29 Traitement de l'ischemie coronaire ou peripherique

Country Status (8)

Country Link
EP (1) EP1699819A2 (fr)
JP (1) JP2007536909A (fr)
KR (1) KR20070006714A (fr)
AU (1) AU2004309090A1 (fr)
CA (1) CA2550727A1 (fr)
MX (1) MXPA06007519A (fr)
WO (1) WO2005063807A2 (fr)
ZA (1) ZA200606268B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2700613C (fr) * 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Cellules angiogeniques provenant d'un perfusat placentaire humain
WO2011130729A2 (fr) * 2010-04-16 2011-10-20 Salk Institute For Biological Studies Procédés de traitement de troubles métaboliques utilisant le fgf
WO2015061331A1 (fr) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Peptides de facteur de croissance des fibroblastes (fgf) 2/fgf1 chimériques et procédés d'utilisation
AU2014340241B2 (en) 2013-10-21 2018-11-01 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
EP3368059A4 (fr) 2015-10-30 2019-03-27 Salk Institute for Biological Studies Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1
JP7333919B2 (ja) * 2017-09-05 2023-08-28 エクセル メッド、エルエルシー 虚血を治療するためのヘパリン組成物
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008828A1 (fr) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Traitements de lesions neuronales liees a l'ischemie, a l'hypoxie ou a la degenerescence neuronale
EP1283268A3 (fr) * 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)
US6395707B1 (en) * 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US7252818B2 (en) * 1998-07-24 2007-08-07 Cardiovascular Biotherapeutics, Inc. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
IL133318A0 (en) * 1999-12-05 2001-04-30 Yeda Res & Dev Proteoglycans and pharmaceutical compositions comprising them
WO2003038054A2 (fr) * 2001-10-31 2003-05-08 New York University Conception et synthese de type structurel d'inhibiteurs de facteur de croissance fibroblastique (fgf), et composes modulateurs de fgf
EP1677831A1 (fr) * 2003-06-05 2006-07-12 Gencell S.A. Plasmide codant un facteur de croissance des fibroblastes pour le traitement de l'hypercholesterolemie ou du diabete associe a des anomalies angiogeniques

Also Published As

Publication number Publication date
ZA200606268B (en) 2008-04-30
JP2007536909A (ja) 2007-12-20
AU2004309090A1 (en) 2005-07-14
WO2005063807A2 (fr) 2005-07-14
EP1699819A2 (fr) 2006-09-13
MXPA06007519A (es) 2007-05-23
WO2005063807A3 (fr) 2005-09-29
KR20070006714A (ko) 2007-01-11

Similar Documents

Publication Publication Date Title
DK2222330T3 (en) Treatment of inflammatory diseases with ACE2
WO2006083182A9 (fr) Utilisation d'antagonistes de myostatine (gdf-8) pour ameliorer la cicatrisation et prevenir les maladies fibreuses
JP2000517174A (ja) ケラチノサイト増殖因子―２（ｋｇｆ―２または線維芽細胞増殖因子―１２、ｆｇｆ―１２）
ES2477498T3 (es) Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular
JPH09510967A (ja) 創傷の治癒
EA007014B1 (ru) Применение il-18 в качестве диагностического маркера
CA2550727A1 (fr) Traitement de l'ischemie coronaire ou peripherique
JP2002507546A (ja) 角質細胞増殖因子−２の治療的使用
JP2002516676A (ja) 遺伝子治療法
KR20200116098A (ko) 항응고제 단백질 및 호중구의 활성화와 관련된 질환을 치료하기 위한 이의 용도
CA2709895C (fr) Traitement de fibroses et de pathologies du foie
US6060460A (en) Use of betaglycan to reduce scarring
Mbachu et al. A monoclonal antibody against cytokine-induced neutrophil chemoattractant attenuates injury in the small intestine in a model of ruptured abdominal aortic aneurysm
JP2002371006A (ja) 肺線維症予防および／または進行防止剤
AU746782B2 (en) Tissue factor for influencing blood vessel formation
JP2000500162A5 (fr)
CN108117615B (zh) 低分子量肝素以及肝素用于制备治疗肺纤维化药物的用途
Ham et al. Degradation of amyloid A precursor protein SAA by macrophage cell lines obtained from amyloid resistant and susceptible strains of mice
Kuroda et al. Effects of viral interleukin 10 introduced by in vivo electroporation on arthrogen-induced arthritis in mice.
JP2001187740A (ja) 創傷治療剤
EP1567197B1 (fr) Compositions pour le traitement ou le prevention des symptomes dependant de l'angiogenese
US6930094B1 (en) Tissue factor for influencing blood vessel formation
JP2003238439A (ja) 虚血治療剤
EP4729066A1 (fr) Antidote
CN118222592A (zh) 编码vegfa和sdf-1的rna组合物及其应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20121231